This article highlights the growing strength of unified European patent enforcement, the decisive impact of early legal action, and why innovative medical technology companies must be ready to act quickly when threatened by competitors.
Read more
The road to getting a patent can be quite long and winding. This can be advantageous for some patent applicants, particularly start-ups and spin-outs, because it spreads out the costs for patent prosecution over a number of years. However, there are times when it may be desirable to speed-up the patent prosecution process. In this article, we explain a popular way to speed-up the process to getting a patent: the aptly named Patent Prosecution Highway.
Read more
In this article we discuss the ever-growing popularity of weight-loss drugs and the new candidates that are emerging as alternatives to the well-known GLP1-based drugs that currently dominate the market.
Read more
Recent patent and clinical trial activity highlights a rising global interest in molecular glue research to improve patient outcomes for cancer, neurodegenerative, and autoimmune disease treatments.
Read more
This article explores a major shift in global patent filings for neurodegenerative disorder therapies over the past decade. Once dominated by big pharma’s small molecules, innovation is now increasingly led by SMEs developing biotherapeutics targeting root causes. This trend reflects rising interest in precision medicine and suggests progress toward more effective treatments beyond symptom management.
Read more
In this article, Trainee Patent Attorney, Emma Lyons, discusses supplementary protection certificates (SPCs) and how they help compensate for the loss of effective patent term caused by regulatory approval delays.
Read more
In our most recent article, Senior Associate and Patent Attorney, Sarah Gibbs, and Trainee Patent Attorney, Jack Braithwaite, discuss how the revocation of Dexcom’s patent on CGM tech by the Unified Patent Court, marked a significant victory for Abbott, in their ongoing patent battle.
Read more
Senior Associate, Edward Rainsford, discusses a referral brought to the Enlarged Board of Appeal. The Enlarged Board of Appeal has been presented with several questions about the extent to which the description and figures should be consulted when interpreting the claims of a patent application. The upcoming decision could clarify claim interpretation in future cases.
Read more
In this article, Appleyard Lees', Senior Associate and Patent Attorney, Sarah Gibbs, explores how the launch of two recently developed malaria vaccines, RTS,S and R21, marks a critical milestone in combating malaria. Sarah explores how integrating these vaccines with existing control measures in Africa sets out a promising path towards near-eradication of malaria.
Read more
The first revocation decision from the Unified Patent Court (UPC) has seen a win for Sanofi and Regeneron in a dispute with Amgen over cholesterol lowering drugs.
Read more
In this episode, Appleyard Lees partners and patent attorneys Ean Davies and Adam Tindall discuss the current challenges in-house IP teams face when it comes to protecting innovation, and look at how the priorities of in-house teams have changed in recent years.
Read more
